The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.
This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. A companion FOA (RFA-HL-23-013) is available for earlier stage projects (initial prototype design/testing). For innovators developing small molecule and biologics, Catalyze has companion initiatives that support therapeutic development (RFA-HL-23-011 and RFA-HL-23-012), and an initiative to support enabling technologies and transformative platforms for HLBS (RFA-HL-23-010). See website for additional information.
- Letter of Intent: 30 days prior to the application due date
- Application Due Dates: March 21, 2022; July 21, 2022; Nov 21, 2022; Feb 21, 2023; July 21, 2023; Nov 21, 2023; Feb 21, 2024; July 22, 2024; Nov 21, 2024
- AIDS Application Due Dates: April 18, 2022; Aug 18, 2022; Dec 21, 2022; April 18, 2023; Aug 18, 2023; Dec 21, 2023; April 18, 2024; Aug 19, 2024; Dec 20, 2024
RFA-HL-23-014 Expiration Date: December 21, 2024
Application budgets must not exceed direct costs of $250,000 per year.
The total budget (Federal award and non-Federal matching contributions) should reflect the actual needs of the overall proposed project. Annual project budgets should reflect the actual costs anticipated in each year.
Cost Matching Funds: The recipient is expected to provide at least a 0.25:1 non-Federal match of the Federal direct costs requested.
The maximum project period is two years. The scope of the project should determine the project period.